Sodiomon B Sirima1, Benjamin Mordmüller2, Paul Milligan3, Ulysse Ateba Ngoa4, Fred Kironde5, Frank Atuguba6, Alfred B Tiono1, Saadou Issifou4, Mark Kaddumukasa5, Oscar Bangre6, Clare Flach3, Michael Christiansen7, Peter Bang7, Roma Chilengi8, Søren Jepsen7, Peter G Kremsner4, Michael Theisen9. 1. Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso. 2. Institute of Tropical Medicine, University of Tübingen, Germany. 3. London School of Hygiene & Tropical Medicine, UK. 4. Institute of Tropical Medicine, University of Tübingen, Germany; Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon. 5. Makerere University College of Health Sciences, Uganda. 6. Navrongo Health Research Centre, Ghana. 7. Statens Serum Institut, Denmark. 8. Centre for Infectious Disease Research in Zambia, Zambia. 9. Statens Serum Institut, Denmark; Centre for Medical Parasitology at Department of International Health, Immunology, and Microbiology, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark. Electronic address: mth@ssi.dk.
Abstract
BACKGROUND:GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3. We assessed efficacy of GMZ2 in children in Burkina Faso, Gabon, Ghana and Uganda. METHODS:Children 12-60months old were randomized to receive three injections of either 100μg GMZ2 adjuvanted with aluminum hydroxide or a control vaccine (rabies) four weeks apart and were followed up for six months to measure the incidence of malaria defined as fever or history of fever and a parasite density ⩾5000/μL. RESULTS: A cohort of 1849 children were randomized, 1735 received three doses of vaccine (868 GMZ2, 867 control-vaccine). There were 641 malaria episodes in the GMZ2/Alum group and 720 in the control group. In the ATP analysis, vaccine efficacy (VE), adjusted for age and site was 14% (95% confidence interval [CI]: 3.6%, 23%, p-value=0.009). In the ITT analysis, age-adjusted VE was 11.3% (95% CI 2.5%, 19%, p-value=0.013). VE was higher in older children. In GMZ2-vaccinated children, the incidence of malaria decreased with increasing vaccine-induced anti-GMZ2 IgG concentration. There were 32 cases of severe malaria (18 in the rabies vaccine group and 14 in the GMZ2 group), VE 27% (95% CI -44%, 63%). CONCLUSIONS:GMZ2 is the first blood-stage malaria vaccine to be evaluated in a large multicenter trial. GMZ2 was well tolerated and immunogenic, and reduced the incidence of malaria, but efficacy would need to be substantially improved, using a more immunogenic formulation, for the vaccine to have a public health role.
RCT Entities:
BACKGROUND:GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Plasmodium falciparum, glutamate-rich protein and merozoite surface protein 3. We assessed efficacy of GMZ2 in children in Burkina Faso, Gabon, Ghana and Uganda. METHODS:Children 12-60months old were randomized to receive three injections of either 100μg GMZ2 adjuvanted with aluminum hydroxide or a control vaccine (rabies) four weeks apart and were followed up for six months to measure the incidence of malaria defined as fever or history of fever and a parasite density ⩾5000/μL. RESULTS: A cohort of 1849 children were randomized, 1735 received three doses of vaccine (868 GMZ2, 867 control-vaccine). There were 641 malaria episodes in the GMZ2/Alum group and 720 in the control group. In the ATP analysis, vaccine efficacy (VE), adjusted for age and site was 14% (95% confidence interval [CI]: 3.6%, 23%, p-value=0.009). In the ITT analysis, age-adjusted VE was 11.3% (95% CI 2.5%, 19%, p-value=0.013). VE was higher in older children. In GMZ2-vaccinated children, the incidence of malaria decreased with increasing vaccine-induced anti-GMZ2 IgG concentration. There were 32 cases of severe malaria (18 in the rabies vaccine group and 14 in the GMZ2 group), VE 27% (95% CI -44%, 63%). CONCLUSIONS:GMZ2 is the first blood-stage malaria vaccine to be evaluated in a large multicenter trial. GMZ2 was well tolerated and immunogenic, and reduced the incidence of malaria, but efficacy would need to be substantially improved, using a more immunogenic formulation, for the vaccine to have a public health role.
Authors: Henriette Prinz; Julia M Sattler; Alison Roth; Johanna Ripp; John H Adams; Friedrich Frischknecht Journal: Parasitol Res Date: 2018-05-24 Impact factor: 2.289
Authors: Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Odilon Nouatin; Ulysse Ateba Ngoa; Javier Ibáñez; Jean Claude Dejon-Agobe; Benjamin Mordmüller; Jean Ronald Edoa; Fabrice Mougeni; Sina Brückner; Aurore Bouyoukou Hounkpatin; Meral Esen; Michael Theisen; Kabirou Moutairou; Stephen L Hoffman; Saadou Issifou; Adrian J F Luty; Marguerite M Loembe; Selidji Todagbé Agnandji; Bertrand Lell; Peter G Kremsner; Ayôla Akim Adegnika Journal: Vaccine Date: 2020-05-05 Impact factor: 3.641
Authors: Ulrik H Mistarz; Susheel K Singh; Tam T T N Nguyen; Will Roeffen; Fen Yang; Casper Lissau; Søren M Madsen; Astrid Vrang; Régis W Tiendrebeogo; Ikhlaq H Kana; Robert W Sauerwein; Michael Theisen; Kasper D Rand Journal: Pharm Res Date: 2017-06-23 Impact factor: 4.200
Authors: Angela M Minassian; Sarah E Silk; Jordan R Barrett; Carolyn M Nielsen; Kazutoyo Miura; Ababacar Diouf; Carolin Loos; Jonathan K Fallon; Ashlin R Michell; Michael T White; Nick J Edwards; Ian D Poulton; Celia H Mitton; Ruth O Payne; Michael Marks; Hector Maxwell-Scott; Antonio Querol-Rubiera; Karen Bisnauthsing; Rahul Batra; Tatiana Ogrina; Nathan J Brendish; Yrene Themistocleous; Thomas A Rawlinson; Katherine J Ellis; Doris Quinkert; Megan Baker; Raquel Lopez Ramon; Fernando Ramos Lopez; Lea Barfod; Pedro M Folegatti; Daniel Silman; Mehreen Datoo; Iona J Taylor; Jing Jin; David Pulido; Alexander D Douglas; Willem A de Jongh; Robert Smith; Eleanor Berrie; Amy R Noe; Carter L Diggs; Lorraine A Soisson; Rebecca Ashfield; Saul N Faust; Anna L Goodman; Alison M Lawrie; Fay L Nugent; Galit Alter; Carole A Long; Simon J Draper Journal: Med (N Y) Date: 2021-06-11